American Diagnostica Inc. (ADI) has terminated an agreement inprinciple to merge with Harrier Inc., Harrier said.Richard Hart, who with his wife owns about 98 percent of privatelyheld ADI, believed ADI would not profit from the merger, Harrier said.ADI and Harrier will, however, continue their collaborative efforts asspelled out in a joint research and development agreement signed inMarch 1993.That agreement called for ADI of Greenwich, Conn., to develop andtest synthetic drugs using Harrier's glycosylation process (to modifyphysical and biological properties of drugs, or to create new ones).New discoveries, and income from them, will be co-owned: 60 percentby Harrier of Los Angeles and 40 percent by ADI.Hart, president and chief executive officer of ADI, was elected to theHarrier board of directors in April 1993 and has now resigned, Harriersaid.
APPOINTMENTS AND ADVANCEMENTSCell Genesys of Foster City, Calif., named Daniel Hoth senior vicepresident and chief operating officer, a newly created position.Albert Halluin joined the law firm of Pennie & Edmonds of MenloPark, Calif., as a partner. Halluin is a patent attorney who specialized inbiotechnology and chemistry.Miles Inc. of West Haven, Conn., named George Scangos president ofMiles Biotechnology. Scangos was senior vice president of research forthe Pharmaceutical Division of Miles.Innovex Diagnostics Inc. of San Diego hired Susan Hochschwender asvice president of research and development and Cathy Swindlehurst asdirector of research.ImmuDyne Inc. of Houston elected Walter Smith to the board ofdirectors.Seragen Inc. of Hopkinton, Mass., promoted Patricia Bacha to seniordirector of preclinical studies, John O'Loughlin to senior director ofbiochemistry, and Helen Maslocka to vice president for investorrelations/corporate communications.
(c) 1997 American Health Consultants. All rights reserved.